Oncolytics Biotech Reports Preclinical Results for Pelareorep + Pan-RAS Inhibitor

What Happened On September 10, 2026, Oncolytics Biotech Inc. (ONCY) filed an 8-K and issued a press release announcing results from a preclinical study evaluating its oncolytic virus pelareorep in combination with a pan‑RAS inhibitor in a RAS‑driven colorectal cancer model. The filing (Exhibit 99.1) contains the press release and the report was signed on behalf of the company by CFO Kirk Look.

Key Details

• Filing date: September 10, 2026 (Form 8-K, Item 8.01 Other Events).
• Subject: Preclinical study results for pelareorep combined with a pan‑RAS inhibitor in a RAS‑driven colorectal cancer model.
• Exhibit included: Press release filed as Exhibit 99.1; cover page interactive data (Exhibit 104) embedded in the filing.
• Authorized signature: Kirk Look, Chief Financial Officer.

Why It Matters This 8-K is a development update on Oncolytics’ preclinical pipeline—specifically a combination approach targeting RAS‑driven colorectal cancer. For investors, preclinical results indicate scientific progress but are early-stage and do not represent clinical or regulatory outcomes. The announcement may be relevant to evaluating the company’s R&D momentum and future clinical plans, but further clinical data and regulatory steps would be required to assess commercial potential.